@article{TP154052,
author = {Gang Xiao and Qianqian Ying and Shengzhi Cui and Zhenli Shen and Like Zheng and Qidong Ye},
title = {Gamma-aminobutyric acid supplementation combined with gonadotropin-releasing hormone analog therapy versus gonadotropin-releasing hormone analog therapy alone for linear growth in children with growth retardation: a retrospective cohort study},
journal = {Translational Pediatrics},
volume = {15},
number = {6},
year = {2026},
keywords = {},
abstract = {Background: Growth retardation is a significant clinical challenge in children with central precocious puberty (CPP) or early and fast puberty (EFP) in children receiving gonadotropin-releasing hormone agonist (GnRHa) therapy and represents an important unmet need in pediatric endocrine practice, particularly where access to recombinant human growth hormone is limited.Methods: This single-center retrospective cohort study included 150 pediatric patients with CPP or EFP (mean age 9.0 years, 83.3% female) who showed growth retardation [growth velocity (GV) 0.05). At 12 months, ΔHtSDS in the GnRHa + GABA group was significantly higher than that in the control group (0.53±0.22 vs. 0.05±0.12; difference 0.48, 95% confidence interval (CI): 0.43–0.53, P},
issn = {2224-4344}, url = {https://tp.amegroups.org/article/view/154052}
}